Moreover, this analysis revealed that SHP1 is also frequently downregulated in a substantial proportion of BL, FL, and primary effusion lymphoma (PEL) tumors (Figure 3), suggesting that SHP1 deficiency could represent a common mechanism of BCR pathway activation in several B cell malignancies. The gene discussed is BCR; the disease is primary effusion lymphoma.